Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMO959 + AAA617 + ARPI in mCRPC
NCT07226986Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Dec 2025
- Primary completion
- Jul 2028
- Countries
- 7
01
Overview
A Phase 2 trial of luxdegalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Novartis. Started Dec 2025; status: recruiting.
02
Drugs
luxdegalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07226986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226986.